Bone turnover markers in HIV disease

AIDS Reviews

Volumn 13, Issue 4, 2011, Pages 240-250

  Haskelberg, Hila ^a   Carr, Andrew ^b   Emery, Sean ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Antiretroviral therapy; Biomarkers; Bone loss; Bone turnover markers; Fracture risk; HIV

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ANTIRETROVIRUS AGENT; CARBOXY TERMINAL TELOPEPTIDE; DEOXYPYRIDINOLINE; DIDANOSINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROCOLLAGEN C PROTEINASE; PYRIDINOLINE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RITONAVIR; SAQUINAVIR; SEX HORMONE; TENOFOVIR; ZIDOVUDINE;

AGE; ALCOHOL CONSUMPTION; BONE BIOPSY; BONE DENSITY; BONE REMODELING; BONE TURNOVER; CIRCADIAN RHYTHM; ETHNICITY; FOOD INTAKE; FRACTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MORPHOMETRICS; OSSIFICATION; OSTEOLYSIS; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SEASONAL VARIATION; SEX;

BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES; BONE REMODELING; FEMALE; FRACTURES, BONE; HIV INFECTIONS; HUMANS; MALE; OSTEOGENESIS; PREVALENCE; RISK ASSESSMENT;

EID: 80655148137     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Institute of Medicine Committee. Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. Washington, USA: National Academies Press, 2010.
2. Neaton J, Neuhaus J, Emery S. Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010. Curr Opin HIV AIDS. 2010;5:480.
3. International Society for Clinical Densitometry (ISCD). Official Positions 2007.
4. Johnell O, Kanis J, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20:1185-94. (Pubitemid 40863806)
5. Kanis J. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359:1929-36. (Pubitemid 34615775)
6. Kanis J, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385-97.
7. National Osteoporosis Foundation (NOF). Clinician's Guide to Prevention and Treatment of Osteoporosis. 2010.
8. Delmas P, Eastell R, Garnero P, Seibel M, Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int. 2000;11:2-17.
9. Brown J, Albert C, Nassar B, et al. Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem. 2009;42:929-42.
10. Carr A, Miller J, Eisman J, Cooper D. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight preantiretroviral therapy. AIDS. 2001;15:703.
11. van Vonderen M, Lips P, van Agtmael M, et al. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS. 2009;23:1367-76.
12. Brown T, Qaqish R. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20:2165-74. (Pubitemid 44684707)
13. McComsey G, Tebas P, Shane E, et al. Bone disease in HIV Infection: A practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51:937-46.
14. Triant V, Brown T, Lee H, Grinspoon S. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008;93:3499-504.
15. Young B, Dao C, Buchacz K, Baker R, Brooks J. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) Compared with the US general population, 2000-2006. Clin Infect Dis. 2011;52:1061-8.
16. Hadjidakis D, Androulakis I. Bone remodeling. Ann NY Acad Sci. 2006;1092:385-96. (Pubitemid 47092355)
17. Andersen T, Sondergaard T, Skorzynska K, et al. A physical mechanism for coupling bone resorption and formation in adult human bone. Am J Pathol. 2009;174:239-47.
18. Sims N, Gooi J. Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol. 2008;19:444-51.
19. Vega D, Maalouf N, Sakhaee K. Clinical Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab. 2007;92:4514-21. (Pubitemid 350223419)
20. Leibbrandt A, Penninger J. RANK/RANKL: regulators of immune responses and bone physiology. Ann NY Acad Sci. 2008;1143:123-50.
21. Claudon A, Vergnaud P, Valverde C, Mayr A, Klause U, Garnero P. New automated multiplex assay for bone turnover markers in osteoporosis. Clin Chem. 2008;54:1554-63.
22. Delmas P, Schlemmer A, Gineyts E, Riis B, Christiansen C. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res. 1991;6:639-44.
23. Seibel M. Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev. 2005;26:97-122.
24. Rissanen J, Suominen M, Peng Z, Halleen J. Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. Calcif Tissue Int. 2008;82:108-15.
25. Garnero P, Delmas P. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab. 1993;77:1046.
26. Diaz Diego E, Guerrero R, de la Piedra C. Six osteocalcin assays compared. Clin Chem. 1994;40:2071-7. (Pubitemid 24346177)
27. Gundberg C, Hanning R, Liu Y, Zlotkin S, Balfe J, Cole D. Clearance of osteocalcin by peritoneal dialysis in children with end-stage renal disease. Pediatr Res. 1987;21:296.
28. Schafer A, Vittinghoff E, Ramachandran R, Mahmoudi N, Bauer D. Laboratory reproducibility of biochemical markers of bone turnover in clinical practice. Osteoporos Int. 2010;21:439-45.
29. Szulc P, Kaufman J, Delmas P. Biochemical assessment of bone turnover and bone fragility in men. Osteoporos Int. 2007;18:1451-61. (Pubitemid 47512683)
30. Fatayerji D, Eastell R. Age-related changes in bone turnover in men. J Bone Miner Res. 1999;14:1203-10. (Pubitemid 29314065)
31. Garnero P, Sornay-Rendu E, Chapuy M, Delmas P. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996;11:337-49. (Pubitemid 26076383)
32. Szulc P, Delmas P. Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int. 2008;19:1683-704.
33. Khosla S, Melton L, Atkinson E, O'Fallon W, Klee G, Riggs B. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab. 1998;83:2266-74. (Pubitemid 28503012)
34. Leder B, Araujo A, Travison T, McKinlay J. Racial and ethnic differences in bone turnover markers in men. J Clin Endocrinol Metab. 2007;92:3453-7. (Pubitemid 47435319)
35. Ju H, Leung S, Brown B, et al. Comparison of analytical performance and biological variability of three bone resorption assays. Clin Chem. 1997;43:1570.
36. Greenspan S, Dresner-Pollak R, Parker R, London D, Ferguson L. Diurnal variation of bone mineral turnover in elderly men and women. Calcif Tissue Int. 1997;60:419-23. (Pubitemid 27183892)
37. Hassager C, Risteli J, Risteli L, Jensen S, Christiansen C. Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women. J Bone Miner Res. 1992;7:1307-11. (Pubitemid 23000971)
38. Woitge H, Scheidt-Nave C, Kissling C, et al. seasonal variation of biochemical indexes of bone turnover: results of a population-based study. J Clin Endocrinol Metab. 1998;83:68-75. (Pubitemid 28498312)
39. Glover S, Garnero P, Naylor K, Rogers A, Eastell R. Establishing a reference range for bone turnover markers in young, healthy women. Bone. 2008;42:623-30.
40. Creighton D, Morgan A, Boardley D, Brolinson P. Weight-bearing exercise and markers of bone turnover in female athletes. J Appl Physiol. 2001;90:565-70. (Pubitemid 32118915)
41. Chen J, Cameron I, Cumming R, et al. Effect of age related chronic immobility on markers of bone turnover. J Bone Miner Res. 2006;21:324-31. (Pubitemid 43265299)
42. Tamaki J, Iki M, Fujita Y, et al. Impact of smoking on bone mineral density and bone metabolism in elderly men: the Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) study. Osteoporos Int. 2011;22:133-41.
43. Clowes J, Hannon R, Yap T, Hoyle N, Blumsohn A, Eastell R. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone. 2002;30:886-90. (Pubitemid 34616018)
44. Ton F, Gunawardene S, Lee H, Neer R. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res. 2005;20:464-70. (Pubitemid 40293495)
45. Ivaska K, Gerdhem P, Åkesson K, Garnero P, Obrant K. Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women. J Bone Miner Res. 2007;22:1155-64. (Pubitemid 351339697)
46. Seeman E, Delmas P. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med. 2006;354:2250.
47. Post T, Cremers S, Kerbusch T, Danhof M. Bone physiology, disease and treatment: towards disease system analysis in osteoporosis. Clin Pharmacokinet. 2010;49:89-118.
48. Kent G, Price R, Gutteridge D, et al. Human lactation: Forearm trabecular bone loss, increased bone turnover, and renal conservation of calcium and inorganic phosphate with recovery of bone mass following weaning. J Bone Miner Res. 1990;5:361-9. (Pubitemid 20276836)
49. Christiansen C, Riis B, Rodbro P. Prediction of rapid bone loss in postmenopausal women. Lancet. 1987;329:1105-8.
50. Lenora J, Ivaska K, Obrant K, Gerdhem P. Prediction of bone loss using biochemical markers of bone turnover. Osteoporos Int. 2007;18:1297-305. (Pubitemid 47300283)
51. Yoshimura N, Hashimoto T, Sakata K, Morioka S, Kasamatsu T, Cooper C. Biochemical markers of bone turnover and bone loss at the lumbar spine and femoral neck: The Taiji Study. Calcif Tissue Int. 1999;65:198-202. (Pubitemid 29380338)
52. Ivaska K, Lenora J, Gerdhem P, Akesson K, Vaananen H, Obrant K. Serial assessment of serum bone metabolism markers identifies women with the highest rate of bone loss and osteoporosis risk. J Clin Endocrinol Metab. 2008;93:2622-32. (Pubitemid 352008529)
53. Rogers A, Hannon R, Eastell R. Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res. 2000;15:1398-404. (Pubitemid 30413874)
54. Lenora J, Ivaska K, Gerdhem P. Use of bone turnover markers in osteoporosis. Clin Rev Bone Miner Metab. 2010;8:1-14.
55. Falchetti A, Masi L, Brandi M. Paget's disease of bone: there's more than the affected skeletal-a clinical review and suggestions for the clinical practice. Curr Opin Rheumatol. 2010;22:410.
56. Costa L, Demers L, Gouveia-Oliveira A, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol. 2002;20:850.
57. Garnero P, Sornay-Rendu E, Claustrat B, Delmas P. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res. 2000;15:1526-36. (Pubitemid 30484522)
58. Ross P, Kress B, Parson R, Wasnich R, Armour K, Mizrahi I. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int. 2000;11:76-82. (Pubitemid 30099514)
59. Ivaska K, Gerdhem P, Väänänen H, Åkesson K, Obrant K. Bone turnover markers and prediction of fracture: A prospective follow-up study of 1040 elderly women for a mean of 9 years. J Bone Miner Res. 2010;25: 393-403.
60. Garnero P, Hausherr E, Chapuy M, et al. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study. J Bone Miner Res. 1996;11:1531-8. (Pubitemid 26331009)
61. Meier C, Nguyen T, Center J, Seibel M, Eisman J. Bone resorption and osteoporotic fractures in elderly men: the dubbo osteoporosis epidemiology study. J Bone Miner Res. 2005;20:579-87. (Pubitemid 40393065)
62. Mellert W, Kleinschmidt A, Schmidt J, et al. Infection of human fibroblasts and osteoblast-like cells with HIV-1. AIDS. 1990;4:527-36.
63. Nacher M, Serrano S, Gonzalez A, et al. Osteoblasts in HIV-infected patients: HIV-1 infection and cell function. AIDS. 2001;15:2239-43. (Pubitemid 34059830)
64. Gibellini D, De Crignis E, Ponti C, et al. HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J Med Virol. 2008;80:1507-14.
65. Cotter E, Malizia A, Chew N, Powderly W, Doran P. HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development. AIDS Res Hum Retrovir. 2007;23:1521-30.
66. Fakruddin J, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem. 2003;278:48251-8. (Pubitemid 37523280)
67. Gibellini D, Borderi M, De Crignis E, et al. RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men. J Med Virol. 2007;79:1446-54. (Pubitemid 47328732)
68. Serrano S, Mariñoso M, Soriano J, et al. Bone remodeling in human immunodeficiency virus-1-infected patients. A histomorphometric study. Bone. 1995;16:185-91.
69. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007;7:292-304. (Pubitemid 46480961)
70. Gough A, Sambrook P, Devlin J, et al. Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol. 1998;25:1282-9. (Pubitemid 28312343)
71. Robinson R, Iqbal S, Abrams K, Al-Azzawi F, Mayberry J. Increased bone resorption in patients with Crohn's disease. Aliment Pharmacol Ther. 1998;12:699-705. (Pubitemid 28369874)
72. Romas E, Gillespie M, Martin T. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone. 2002;30:340-6. (Pubitemid 34154863)
73. Trebec-Reynolds D, Voronov I, Heersche J, Manolson M. IL-1alpha and IL-1beta have different effects on formation and activity of large osteoclasts. J Cell Bioch. 2010;109:975-82.
74. Edwards C, Williams E. The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis. Osteoporos Int. 2010;21:1287-93.
75. Ding C, Parameswaran V, Udayan R, Burgess J, Jones G. Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab. 2008;93:1952-8. (Pubitemid 351656543)
76. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou N. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone. 2003;32:1-7. (Pubitemid 36173806)
77. Connolly N, Riddler S, Rinaldo C. Proinflammatory cytokines in HIV disease-a review and rationale for new therapeutic approaches. AIDS Rev. 2005;7:168-80. (Pubitemid 41671917)
78. Aukrust P, Liabakk N-B, Muller F, Lien E, Espevik T, Froland S. Serum levels of tumor necrosis factor-α (TNFα) and soluble TNF receptors in human immunodeficiency virus type 1 infection: correlations to clinical, immunologic, and virologic parameters. J Infect Dis. 1994;169:420-4. (Pubitemid 24045606)
79. Yin M, McMahon D, Ferris D, et al. Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 2010;95:620-9.
80. Brown T, McComsey G, King M, Qaqish R, Bernstein B, da Silva B. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J AIDS. 2009;51:554-61.
81. Takayanagi H, Ogasawara K, Hida S, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature. 2000;408:600-5.
82. Kong Y, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999;402:304-9. (Pubitemid 129516268)
83. Weitzmann M, Cenci S, Rifas L, Haug J, Dipersio J, Pacifici R. T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. J Bone Miner Res. 2001;16:328-37. (Pubitemid 32105414)
84. Hazenberg M, Stuart J, Otto S, et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood. 2000;95:249-55. (Pubitemid 30017249)
85. Ofotokun I, Weitzmann N, Vunnava A, et al. HAART-induced immune reconstitution: a driving force behind bone resorption in HIV/AIDS. 18th CROI. Boston, 2011.
86. Pan G, Kilby M, McDonald J. Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors. AIDS Res Hum Retroviruses. 2006;22:1131-41. (Pubitemid 44904264)
87. Pan G, Wu X, McKenna M, Feng X, Nagy T, McDonald J. AZT enhances osteoclastogenesis and bone loss. AIDS Res Hum Retroviruses. 2004;20:608-20. (Pubitemid 38813658)
88. Grigsby I, Pham L, Mansky L, Gopalakrishnan R, Carlson A, Mansky K. Tenofovir treatment of primary osteoblasts alters gene expression profiles: Implications for bone mineral density loss. Biochem Biophys Res Commun. 2010;394:48-53.
89. Nolan D, Upton R, McKinnon E, et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS. 2001;15:1275.
90. Teichmann J, Stephan E, Lange U, et al. Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect. 2003;46:221-7. (Pubitemid 36758180)
91. Konishi M, Takahashi K, Yoshimoto E, Uno K, Kasahara K, Mikasa K. Association between osteopenia/osteoporosis and the serum RANKL in HIV-infected patients. AIDS. 2005;19:1240-1. (Pubitemid 41059272)
92. Seminari E, Castagna A, Soldarini A, et al. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Med. 2005;6:145-50. (Pubitemid 40740329)
93. Calmy A, Fux C, Norris R, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis. 2009;200:1746-54.
94. Grijsen M, Vrouenraets S, Steingrover R, et al. High prevalence of reduced bone mineral density in primary HIV-1-infected men. AIDS. 2010;24:2233-8.
95. Welz T, Childs K, Ibrahim F, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS. 2010;24:1923.
96. Fausto A, Bongiovanni M, Cicconi P, et al. Potential predictive factors of osteoporosis in HIV-positive subjects. Bone. 2006;38:893-7. (Pubitemid 44500653)
97. Piso R, Rothen M, Rothen J, Stahl M. Markers of bone turnover are elevated in patients with antiretroviral treatment independent of the substance used. J Acquir Immune Defic Syndr. 2011;56:320.
98. Mora S, Zamproni I, Cafarelli L, et al. Alterations in circulating osteoimmune factors may be responsible for high bone resorption rate in HIV-infected children and adolescents. AIDS. 2007;21:1129-35.
99. Fux C, Rauch A, Simcock M, et al. Short communication Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antivir Ther. 2008;13:1077-82.
100. Mondy K, Yarasheski K, Powderly W, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36:482-90. (Pubitemid 36241317)
101. Aukrust P, Haug C, Ueland T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab. 1999;84:145-50. (Pubitemid 29036693)
102. Dolan S, Kanter J, Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 2006;91:2938-45. (Pubitemid 44271739)
103. Stellbrink H, Orkin C, Arribas J, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51:963.
104. van Vonderen M, Mallon P, Murray B, et al. Changes in bone biomarkers in ARV-naïve HIV+ men randomized to NVP/LPV/r or AZT/3TC/LPV/r help explain limited loss of bone mineral density over the first 12 months after ART Initiation. 18th CROI. Boston, 2011.
105. Haskelberg H, Hoy J, Amin J, Ebeling P, Emery S, Carr A. Lower body fat mass and lower bone formation predict greater bone loss with tenofovir in HIV-infected adults. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy 2011.
106. Hoy J, Grund B, Roediger M, et al. Plasma markers of bone loss and bone formation decrease with intermittent antiretroviral therapy predict change in bone mineral density. 13th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV. Rome, Italy, 2011.
107. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis. 2009;49:1591.
108. Stellbrink H, Orkin C, Arribas J, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT Study. Clin Infect Dis. 2010;51:963-72.
109. Aukrust P, Haug C, Ueland T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab. 1999; 84:145.
110. Teichmann J, Stephan E, Discher T, et al. Changes in calciotropic hormones and biochemical markers of bone metabolism in patients with human immunodeficiency virus infection. Metabolism. 2000;49:1134-9.
111. Huang J, Meixner L, Fernandez S, McCutchan J. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS. 2009;23:51-7.
112. Bauer D, Black D, Garnero P, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res. 2004;19:1250-8. (Pubitemid 41094365)
113. Clowes J, Peel N, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004; 89:1117.
114. Vasikaran S, Eastell R, Bruyère O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22:391-420.
115. Bergmann P, Body J, Boonen S, et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract. 2009;63:19-26.
116. Nishizawa Y, Nakamura T, Ohta H, et al. Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). J Bone Miner Metab. 2005;23:97-104. (Pubitemid 40591031)
117. Lewiecki E, Watts N. Assessing response to osteoporosis therapy. Osteoporos Int. 2008;19:1363-8.